SOPH May 2024 5.000 call
| Previous Close | 0.3000 |
| Open | 0.5000 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.3000 - 0.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 107 |
ZacksWall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireSOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance ReaffirmedBOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue grew 13% year-over-year to $15.8 million; Constant currency revenue excluding COVID-related revenue grew 12% year-over-yearGross
- GlobeNewswire
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be availa
